Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
28 Mar 24
6-K
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results
7 Mar 24
6-K
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary
3 Jan 24
6-K
Current report (foreign)
9 Nov 23
EFFECT
Notice of effectiveness
6 Nov 23
CORRESP
Correspondence with SEC
1 Nov 23
F-3/A
Shelf registration (foreign) (amended)
30 Oct 23
F-3
Shelf registration (foreign)
16 Oct 23
6-K
Current report (foreign)
14 Aug 23
6-K
Current report (foreign)
8 Aug 23
6-K
Current report (foreign)
3 Jul 23
8-K
Departure of Directors or Certain Officers
16 Jun 23
8-K
Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update
5 Jun 23
RW
Registration withdrawal request
2 Jun 23
S-1/A
IPO registration (amended)
19 May 23
8-K
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
S-1/A
IPO registration (amended)
22 Mar 23
S-1/A
IPO registration (amended)
21 Mar 23
ARS
2022 FY
Annual report to shareholders
21 Mar 23
10-K
2022 FY
Annual report
20 Mar 23
S-1/A
IPO registration (amended)
22 Feb 23
8-K
Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis
21 Feb 23
S-1/A
IPO registration (amended)
21 Feb 23
8-K
Results of Operations and Financial Condition
21 Feb 23
S-1
IPO registration
13 Jan 23
8-K
Regulation FD Disclosure
11 Jan 23
8-K
Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis
3 Jan 23
8-K/A
Financial Statements and Exhibits
29 Nov 22
8-K
Other Events
16 Nov 22
8-K
Chemomab Announces Appointment of Matthew Frankel, MD, MBA
14 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
S-8
Registration of securities for employees
15 Aug 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
8-K
Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
12 Aug 22
8-K
Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors
21 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 22
8-K
Departure of Directors or Certain Officers
1 Jun 22
DEFA14A
Additional proxy soliciting materials
31 May 22
10-Q
2022 Q1
Quarterly report
12 May 22
Latest ownership filings
SC 13D/A
OrbiMed Israel BioFund GP Limited Partnership
11 Mar 24
SC 13D/A
OrbiMed Israel BioFund GP Limited Partnership
15 Nov 23
4
Nissim Darvish
5 Jul 23
4
Jill M. Quigley
20 Jun 23
4
Sigal Fatal
16 Jun 23
3
Sigal Fatal
5 Jun 23
4
Alan Charles Moses
23 Mar 23
4
Claude Nicaise
23 Mar 23
4
Neil Harris Cohen
23 Mar 23
4
Nissim Darvish
23 Mar 23
4
Change in insider ownership
5 Jan 23
SC 13D/A
OrbiMed Israel BioFund GP Limited Partnership
5 Jan 23
4
George Adi Mor
5 Jan 23
4
Neil Harris Cohen
18 Nov 22
4
George Adi Mor
17 Nov 22
SC 13D/A
Mor George Adi
17 Nov 22
3
Matthew Bejosa Frankel
15 Nov 22
3
Jill M. Quigley
21 Jun 22
4
Donald Marvin
21 Jun 22
4
Joel Michael Maryles
25 May 22
4
Neil Harris Cohen
19 May 22
4
Joel Michael Maryles
21 Mar 22
4
Donald Marvin
21 Mar 22
4
Dale R Pfost
15 Mar 22
4
Neil Harris Cohen
15 Mar 22
4
Nissim Darvish
14 Mar 22
4
Nissim Darvish
9 Mar 22
4
Claude Nicaise
9 Mar 22
4
Neil Harris Cohen
9 Mar 22
4
Alan Charles Moses
9 Mar 22
4
Joel Michael Maryles
9 Mar 22
SC 13G/A
Gabriel Capital Management Ltd.
10 Feb 22
SC 13D
Mor George Adi
20 Jan 22
4
Neil Harris Cohen
8 Dec 21
3
Donald Marvin
12 Nov 21
3
Dale R Pfost
4 Nov 21
4
Sigal Fatal
10 May 21
4
STEPHEN P SQUINTO
21 Apr 21
4
Claude Nicaise
21 Apr 21
4
Alan Charles Moses
21 Apr 21